MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
4.240
+0.050 (1.19%)
At close: Nov 10, 2026, 4:00 PM EST
4.210
-0.030 (-0.71%)
After-hours: Nov 10, 2026, 5:55 PM EST
MannKind Revenue
MannKind had revenue of $101.87M in the quarter ending September 30, 2026, with 24.04% growth. This brings the company's total for the last twelve months to $413.37M, up 31.74% year-over-year. In the year 2025, MannKind had annual revenue of $348.97M with 22.23% growth. That makes MannKind the 12,394th largest company in the world by revenue and 2,409th in the United States.
Revenue (ttm)
$413.37M
Revenue Growth
+31.74%
P/S Ratio
3.28
Revenue / Employee
$698,262
Employees
592
Market Cap
1.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 348.97M | 63.46M | 22.23% |
| Dec 31, 2024 | 285.50M | 86.54M | 43.50% |
| Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
| Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
| Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
| Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
| Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
| Dec 31, 2018 | 27.86M | 16.11M | 137.20% |
| Dec 31, 2017 | 11.75M | -163.01M | -93.28% |
| Dec 31, 2016 | 174.76M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UroGen Pharma | 250.25M |
| Nektar Therapeutics | 54.59M |
| Omeros | 38.42M |
| Inhibrx Biosciences | 1.30M |
| Silence Therapeutics | 615.00K |
MNKD News
- 11 hours ago - MannKind to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 days ago - MannKind price target raised to $10 from $8 at Cantor Fitzgerald - TheFly
- 5 days ago - MannKind reports Q3 adjusted EPS (1c), consensus (1c) - TheFly
- 5 days ago - MannKind Earnings Call Transcript: Q3 2026 - Transcripts
- 5 days ago - MannKind Earnings release: Q3 2026 - Filings
- 5 days ago - MannKind Quarterly report: Q3 2026 - Filings
- 5 days ago - MannKind Slides: Q3 2026 - Filings
- 12 days ago - MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026 - GlobeNewsWire